Management of Elevated PTH in Elderly Dialysis Patients

Understanding the Expected PTH Range

The target PTH range for dialysis patients is 150-300 pg/mL, as suppressing PTH to normal ranges can cause adynamic bone disease with increased fracture risk, according to the American College of Cardiology 1, 2
PTH levels 2-9 times the upper limit of normal (approximately 150-600 pg/mL) are considered acceptable in dialysis patients, though the 2017 KDIGO guidelines acknowledge uncertainty about the optimal range 3, 4
Targeting normal PTH levels (<65 pg/mL) in dialysis patients is harmful, causing adynamic bone disease, increasing fracture risk, and impairing the skeleton's ability to buffer calcium-phosphate loads, as stated by the National Kidney Foundation 1, 2

Measure serum calcium, phosphorus, and intact PTH to establish baseline, as recommended by the National Kidney Foundation 1
Check 25-hydroxyvitamin D levels—if <30 ng/mL, replete with ergocalciferol 50,000 IU monthly, according to the American College of Cardiology 1, 2

Target serum phosphorus 3.5-5.5 mg/dL before initiating any active vitamin D therapy, as recommended by the National Kidney Foundation 1, 5
Initiate dietary phosphorus restriction to 800-1,000 mg/day while maintaining adequate protein intake of 1.0-1.2 g/kg/day, according to the American College of Cardiology 1, 5

For PTH 300-800 pg/mL, consider active vitamin D therapy (calcitriol or paricalcitol) if phosphorus <4.6 mg/dL, as recommended by the National Kidney Foundation 1, 2
For PTH >800 pg/mL with hypercalcemia/hyperphosphatemia, consider parathyroidectomy if refractory to medical therapy after 3-6 months of optimization, according to the American College of Surgeons 1, 5

The KDIGO Work Group noted lack of consensus on whether cinacalcet should be first-line therapy, but secondary analyses of the EVOLVE trial suggested particular benefit in older patients (age interaction P=0.04), as stated by the Kidney Disease: Improving Global Outcomes (KDIGO) organization 3
Treatment choice should be guided by individual considerations including concomitant therapies, current calcium and phosphate levels, and patient-specific factors, according to the American Geriatrics Society 3
In elderly patients with multiple comorbidities, the risk-benefit ratio for treating moderate PTH elevations (300-600 pg/mL) may not be favorable—reserve aggressive therapy for severe and progressive hyperparathyroidism, as recommended by the National Kidney Foundation 3